menu
    • menu

    Company profile for Windward Bio

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Windward Bio is a clinical-stage drug development company focused on advanced immunological diseases, with an initial emphasis on severe respiratory conditions. Led by a team of experienced biopharmaceutical executives, the company develops innovative treatments, including a thymic stromal lymphopoietin (TSLP) monoclonal antibody in phase 2 trials and novel bispecific programs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Windward BioSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Basel, Basel-Stadt
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://windwardbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Windward Bio Expands Pipeline with WIN-027 Bispecific Antibody
    Windward Bio Expands Pipeline with WIN-027 Bispecific Antibody

    22 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/22/3208925/0/en/Windward-Bio-Expands-Immunology-Pipeline-With-WIN027-a-Long-Acting-Clinical-Stage-Bispecific-Targeting-TSLP-and-IL-13.html

    GLOBENEWSWIRE
    22 Dec 2025
    Share Share
    Windward Bio Begins Global Phase 2 Asthma Trial of SKB378/WIN378
    Windward Bio Begins Global Phase 2 Asthma Trial of SKB378/WIN378

    23 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kelun-biotechs-partner-windward-bio-announces-initiation-of-a-global-phase-2-asthma-trial-of-skb378win378-302511998.html

    PR NEWSWIRE
    23 Jul 2025
    Share Share
    Windward Bio Begins Global Phase 2 Asthma Trial for WIN378
    Windward Bio Begins Global Phase 2 Asthma Trial for WIN378

    23 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/23/3120231/0/en/Windward-Bio-Initiates-Global-Phase-2-Asthma-Trial-of-WIN378-a-Potential-Best-in-Disease-Long-Acting-Anti-TSLP-Monoclonal-Antibody.html

    GLOBENEWSWIRE
    23 Jul 2025
    Share Share
    Novo Invests $200M for Windward Bio's Asthma and COPD Treatments
    Novo Invests $200M for Windward Bio's Asthma and COPD Treatments

    10 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/novo-holdings-invests-in-200m-series-a-for-windward-bio-launch-to-advance-long-acting-treatments-for-asthma-and-copd-302348007.html

    PR NEWSWIRE
    10 Jan 2025
    Share Share
    Windward Bio Launches With $200M Series A For Anti-TSLP Antibody
    Windward Bio Launches With $200M Series A For Anti-TSLP Antibody

    10 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/10/3007703/0/en/Windward-Bio-Launches-With-200-Million-Series-A-Financing-to-Develop-Phase-2-Ready-Long-Acting-Anti-TSLP-Antibody-With-Best-in-Class-Potential-in-Asthma-and-COPD.html

    GLOBENEWSWIRE
    10 Jan 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search